Improvements in Systemic Therapies for Advanced Malignant Mesothelioma-Reference-Cited by-同舟云学术

Improvements in Systemic Therapies for Advanced Malignant Mesothelioma

Published:2023-06-21 Issue:13 Volume:24 Page:10415
ISSN:1422-0067
Container-title:International Journal of Molecular Sciences
language:en
Short-container-title:IJMS

Author:

Deiana Chiara¹²^ORCID,Fabbri Francesca¹²,Tavolari Simona¹²,Palloni Andrea¹²^ORCID,Brandi Giovanni¹²

Affiliation:

1. Medical Oncology, IRCCS Azienda Ospedaliera, Universitaria di Bologna, 40138 Bologna, Italy

2. Department of Medical and Surgical Sciences, University of Bologna, 40138 Bologna, Italy

Abstract

Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy associated with poor prognosis and a 5-year survival rate of 12%. Many drugs have been tested over the years with conflicting results. The aim of this review is to provide an overview of current therapies in MPM and how to best interpret the data available on these drugs. Furthermore, we focused on promising treatments under investigation, such as immunotherapy with targets different from anti-PD-1/PD-L1 inhibitors, vaccines, target therapies, and metabolism-based strategies.

Funder

Italian Ministry of Health

Fondazione Donato-Venturi

Publisher

MDPI AG

Subject

Inorganic Chemistry,Organic Chemistry,Physical and Theoretical Chemistry,Computer Science Applications,Spectroscopy,Molecular Biology,General Medicine,Catalysis

Link

https://www.mdpi.com/1422-0067/24/13/10415/pdf

Reference98 articles.

1. North-south gradient of mesothelioma and asbestos consumption-production in the United States-Progresses since the 1st asbestos partial ban in Am;Sun;J. Ind. Med.,2019

2. CDC (2023, April 14). Incidence of Malignant Mesothelioma, 1999–2018, Available online: https://www.cdc.gov/cancer/uscs/about/data-briefs/no27-incidence-malignant-mesothelioma-1999-2018.htm.

3. (2023, April 14). Survival Rates for Malignant Mesothelioma. Available online: https://www.cancer.org/cancer/malignant-mesothelioma/detection-diagnosis-staging/survival-statistics.html.

4. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma;Vogelzang;J. Clin. Oncol.,2003

5. Randomized phase iii study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: An intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada;Gaafar;J. Clin. Oncol.,2005

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum Calretinin and Genetic Variability as a Prognostic and Predictive Factor in Malignant Mesothelioma;International Journal of Molecular Sciences;2023-12-22

2. The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future Directions;Cancers;2023-12-12